Key Findings From Recent Trials

Basic Largactil Information

• INN (International Nonproprietary Name): Chlorpromazine
• Brand Names Available In United Kingdom: Largactil — tablets (10 mg, 25 mg, 50 mg, 100 mg), oral solution and injection.
• ATC Code: N05AA01 (Phenothiazines with aliphatic side-chain; first‑generation antipsychotic).
• Forms & Dosages: Tablets 10 mg, 25 mg, 50 mg, 100 mg, 200 mg; oral solution commonly 10 mg/mL; injection 25 mg/mL.
• Manufacturers In United Kingdom: Historically marketed as Largactil by Sanofi in Europe; multiple generic manufacturers and global suppliers produce chlorpromazine hydrochloride.
• Registration Status In United Kingdom: Marketed as Largactil in the UK with licensed tablet, oral solution and injectable forms; prescription‑only and listed on the WHO Model List of Essential Medicines.
• OTC / Rx Classification: Prescription‑only (Rx) in all jurisdictions.

Major 2022–2025 Studies

Worried whether chlorpromazine still works in modern practice?

Recent clinical syntheses from 2022 to 2025 reinforce chlorpromazine’s role in acute psychosis and agitation.

Randomised controlled trial meta‑analyses and large observational cohorts consistently show short‑term symptom reduction at usual acute dosing ranges.

Emergency psychiatry datasets still report effective rapid sedation using intramuscular or intravenous chlorpromazine when formulation choice is limited.

These contemporary analyses match historic effect sizes for first‑generation antipsychotics in controlling positive psychotic symptoms.

The evidence base supports use for immediate control rather than preferred long‑term maintenance for most patients.

Main Outcomes

Clinically meaningful symptom reduction in acute psychosis at doses commonly used for emergencies.

Rapid calming in agitated patients when parenteral administration is needed.

Similar short‑term efficacy to other typical antipsychotics in emergency settings.

Safety Observations

Newer surveillance flagged more hypotension and sedation compared with many second‑generation antipsychotics.

Pharmacovigilance reports reinforced risks of QT prolongation and rare but serious syndromes such as neuroleptic malignant syndrome.

Population studies continue to show persistent risk of tardive dyskinesia with long‑term use.

Clinical Mechanism Of Action

Are you wondering how largactil calms severe agitation and psychosis?

Chlorpromazine reduces overactive brain signalling by blocking several receptors that drive excitement and stress.

That action helps reduce hallucinations, delusions and dangerous agitation.

Layman’s Explanation

It calms messages between nerve cells that are too active.

It also blocks histamine and muscarinic receptors, which explains why many people feel sleepy and have a dry mouth.

Blocking dopamine receptors produces the antipsychotic benefit but also explains movement side‑effects.

Scientific Breakdown

Primary antagonism at dopamine D2 receptors in the mesolimbic pathway reduces positive psychotic symptoms.

Secondary antagonism at 5‑HT2, H1, M1 and α1 receptors contributes to mood stabilisation, sedation, anticholinergic effects and orthostatic hypotension.

Metabolism is hepatic via CYP pathways and active metabolites contribute to duration of effect.

Receptor-Level Nuances

D2 occupancy correlates with antipsychotic effect and with extrapyramidal symptoms.

Relative 5‑HT2 antagonism is minor compared with many atypical antipsychotics, so benefits for negative symptoms are limited.

Pharmacokinetics (Brief)

Oral absorption is variable between patients.

Tablets are available from 10 mg up to 200 mg internationally and 10–100 mg strengths are commonly supplied as Largactil in the UK.

Parenteral injection is commonly 25 mg/mL for acute management.

Scope Of Approved And Off-Label Use

What is largactil licensed for, and where might a prescriber use it off‑label?

In the UK, largactil is supplied as tablets (10–100 mg), an oral solution and an injectable preparation, aligning with product information.

United Kingdom Approvals

Licensed indications include schizophrenia and other psychotic disorders, psychomotor agitation and severe short‑term anxiety where indicated.

It is also approved for nausea and vomiting when indicated and for preoperative sedation.

It remains prescription‑only and is on the WHO Essential Medicines list.

Notable Off-Label Trends

Clinicians still report occasional off‑label use for intractable hiccups and refractory nausea when other antiemetics fail.

In palliative care some teams use low doses for symptom control when other options are unsuitable.

Paediatric use is occasional and weight‑adjusted (about 0.5–0.55 mg/kg per dose) with close monitoring for side‑effects.

In lower‑resource settings or when atypicals are contraindicated, chlorpromazine sometimes remains a maintenance option despite tolerability concerns.

Contemporary stewardship encourages the lowest effective dose and time‑limited courses to reduce tardive dyskinesia and cardiovascular risk.

Dosage Strategy

How will a prescriber start largactil and what should patients expect about dose changes?

Initiate low and titrate to clinical response while watching for sedation and orthostatic hypotension.

General Dosing

Typical maintenance ranges from 200–800 mg per day divided into two to four doses for adults.

Initial control may need higher divided dosing during acute episodes.

Parenteral forms (25 mg/mL injection) provide rapid onset for agitation and psychomotor disturbance.

Adjust dose downward in the elderly and in hepatic or severe renal impairment.

Condition-Specific Dosing

Schizophrenia and Acute Psychosis: Start 25–100 mg three times daily and escalate towards therapeutic range with monitoring for extrapyramidal symptoms and vitals.

Nausea/Vomiting: 10–25 mg orally every 4–6 hours following product information; use the lowest effective dose.

Bipolar Mania: Use similar acute antipsychotic dosing to control agitation and psychosis.

Preoperative Anxiety: 25–50 mg one hour before a procedure.

Paediatrics: Approximately 0.5–0.55 mg/kg per dose every 4–6 hours with strict supervision.

Missed Dose Guidance: Take when remembered unless close to the next dose; do not double up.

Safety Protocols

What are the main safety checks before and during largactil treatment?

Contraindications

Absolute contraindications include comatose states or severe central nervous system depression and known hypersensitivity to phenothiazines.

Other absolute contraindications are severe bone marrow depression, pheochromocytoma and infants under six months.

Use with caution and close monitoring in hepatic or renal impairment, significant cardiovascular disease (notably QT risk), a history of seizures, Parkinson’s disease and dementia.

Adverse Effects

Common mild to moderate effects include drowsiness, dry mouth, blurred vision, constipation and orthostatic hypotension.

Weight gain, photosensitivity and extrapyramidal symptoms such as tremor, rigidity and akathisia are also frequently reported.

Serious but less frequent risks include tardive dyskinesia, neuroleptic malignant syndrome, leukopenia, seizures and QT prolongation.

Monitoring Protocols: Baseline ECG for those with cardiac risk factors, blood counts if agranulocytosis suspected, and liver function tests when clinically indicated.

Risk Mitigation: Use the lowest effective dose, review ongoing need frequently, and consider a switch to an atypical antipsychotic for long‑term therapy where tolerability is a concern.

Interaction Mapping

Which foods or medicines change how largactil works or increase risk?

Food Interactions

No major food‑binding issues are documented, but alcohol potentiates central nervous system depression and orthostatic hypotension.

Advise patients to avoid alcohol during treatment and to be cautious with activities requiring alertness.

Drug Combinations To Avoid

CNS depressants such as benzodiazepines and opioids increase sedation and respiratory depression risk when combined with chlorpromazine.

Combine with caution when prescribing other QT‑prolonging drugs (certain antiarrhythmics, macrolide antibiotics and some antidepressants); obtain an ECG when indicated.

CYP inhibitors or inducers may alter chlorpromazine plasma levels — monitor clinical effect and adjust dose if required.

Avoid routine combinations with other dopamine antagonists unless clinically justified, due to increased extrapyramidal and tardive dyskinesia risk.

Anticholinergic co‑medication worsens dry mouth, constipation and urinary retention, while alpha‑blockers can exacerbate hypotension.

Coordinate use with anaesthetists perioperatively because chlorpromazine can potentiate hypotension with anaesthetic agents.

Patient Experience Analysis

What do patients and carers say about largactil in real life?

Survey Data

UK outpatient surveys and observational cohorts report mixed satisfaction with chlorpromazine.

Patients often value effective control of acute psychosis but complain about sedation, weight gain and cognitive dulling.

Longitudinal comparisons indicate a higher burden of extrapyramidal symptoms versus atypical antipsychotics, which can affect adherence.

Forum Trends

Common patient concerns include daytime somnolence that interferes with work or study and photosensitivity affecting outdoor activities.

Many users express anxiety about long‑term movement disorders such as tardive dyskinesia.

Positive experiences frequently cite rapid calming in crisis situations and affordability because generic chlorpromazine and Largactil are inexpensive.

Carers report that injectable forms can provide quick control of dangerous agitation when alternatives are not immediately available.

Patient education points emphasised by peers include timing doses to limit daytime sedation, vigilance for involuntary movements and reporting palpitations or syncope promptly.

Distribution And Pricing Landscape

Can patients obtain largactil easily and what does it cost?

Chlorpromazine is widely available as a generic and as Largactil in the UK with tablets, oral solution and 25 mg/mL injections commonly stocked.

Major generics and historical brands supply UK pharmacies, and global manufacturers maintain multiple sources for tablets and ampoules.

Because it is included on the WHO Essential Medicines list and available generically, acquisition costs remain low on NHS formularies.

Injectables cost more per dose and require careful handling, but remain used in inpatient and emergency settings.

Market trends from 2022–2025 show reduced long‑term prescribing in favour of atypicals, while acute and inpatient niche demand persists.

Supply chains can experience intermittent shortages of particular dosages, so prescribers should identify therapeutic alternatives as a contingency.

In our online pharmacy, largactil is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

How does largactil compare with other antipsychotics and when might a clinician choose a different drug?

Comparison Table

Chlorpromazine sits among typical phenothiazines and is contrasted with other typicals such as haloperidol and perphenazine, and with atypicals including risperidone, olanzapine and quetiapine.

Chlorpromazine provides broad receptor blockade and reliable acute efficacy, with multiple formulations including an injectable 25 mg/mL ampoule.

Pros And Cons

• Pros: Established acute efficacy, low acquisition cost, many formulations including injectable options.
• Cons: Sedation, anticholinergic burden, orthostatic hypotension and higher risk of extrapyramidal symptoms and tardive dyskinesia with long‑term use.

Haloperidol offers strong D2 blockade with lower anticholinergic effects but a high EPS risk.

Atypical antipsychotics generally offer better long‑term tolerability for many patients, while clozapine remains reserved for refractory schizophrenia with intensive monitoring.

Choice depends on urgency (need for an injectable), comorbidity such as cardiac disease or hepatic impairment, and long‑term risk tolerance.

Regulatory Status

What is the official standing of largactil and are there special national cautions?

Chlorpromazine (INN) is classified under ATC N05AA01 and is prescription‑only across jurisdictions.

In the UK it is marketed as Largactil in tablet, oral solution and injectable forms consistent with product information.

It retains approvals for schizophrenia, behavioural disturbance, antiemetic use and preoperative sedation in many European formularies.

Globally it appears on the WHO Model List of Essential Medicines, supporting NHS and international procurement.

Regulatory cautions commonly require clear labelling about tardive dyskinesia, neuroleptic malignant syndrome and QT prolongation.

For paediatric and elderly use regulators advise dose adjustments and close monitoring; local formularies may restrict long‑term use where safer alternatives exist.

Consolidated FAQ

What are the quick answers patients and prescribers ask most?

Dosing & Switching

Q: Is largactil still used in the UK?

A: Yes. It remains used, especially for acute agitation, some antiemetic uses when other treatments have failed, and where specific formulations are needed.

Q: How to switch from chlorpromazine to an atypical?

A: Cross‑titration is the usual approach: gradually reduce chlorpromazine while initiating the atypical and monitor closely for withdrawal effects and extrapyramidal symptoms, taking cardiac and hepatic status into account.

Safety Questions

Q: What monitoring is essential?

A: Baseline ECG if cardiac risk exists, regular assessment for extrapyramidal symptoms, temperature and creatine kinase if neuroleptic malignant syndrome is suspected, and blood counts when clinically indicated.

Q: Pregnancy and breastfeeding?

A: Use only if the benefit outweighs the risk and in consultation with obstetrics and relevant specialists.

Visual Guide

Which images help patients and clinicians understand largactil safely?

Key Visuals To Include

• Tablet and ampoule imagery showing Largactil tablet strengths (10–100 mg) and 25 mg/mL injectable ampoule with clear labelling.
• Receptor map infographic showing D2, 5‑HT2, H1, M1 and α1 blockade linked to common side‑effects.
• Dosing flowchart contrasting acute versus maintenance pathways and showing age adjustments.
• Safety checklist graphic: baseline ECG, orthostatic BP, baseline LFTs and follow‑up schedule.

Interpretation Tips

Pair all images with short captions specifying UK formulations and emphasising prescription‑only status.

For patient leaflets include practical advice on avoiding alcohol, recognising extrapyramidal symptoms and when to seek emergency care.

Storage And Transport

How should largactil be stored and what should pharmacies and patients know when transporting it?

Store at room temperature (20–25°C) and protect from moisture and light.

Tablets and oral solutions should remain in their original packaging and be kept out of reach of children.

Injectable ampoules (25 mg/mL) must not be frozen and should be inspected for particulate matter before use.

For NHS supply chains maintain manufacturer‑recommended storage conditions and record batch details for pharmacovigilance.

Transport in secure, temperature‑controlled conditions for large or international shipments and separate injectables to avoid breakage.

For community prescribing advise patients to avoid prolonged exposure to heat and to return unused medicines via a pharmacy take‑back or follow local NHS waste protocols.

Guidelines For Proper Use

What checks should prescribers and pharmacists complete before handing out largactil?

Prescriber Checklist

• Confirm the indication and assess whether an atypical antipsychotic is preferable for long‑term treatment.
• Check absolute contraindications: comatose states, phenothiazine hypersensitivity, severe bone marrow depression, pheochromocytoma and infants under six months.
• Baseline assessments: ECG if cardiac risk, orthostatic blood pressure, liver/renal profile where indicated, and a full medication reconciliation for interactions.
• Plan dosing: start low, titrate to response and schedule a review with a deprescribing plan if appropriate.

Patient Counselling Points

Explain likely benefits for acute symptom control and common side‑effects including sedation, dry mouth, constipation and photosensitivity.

Advise against alcohol and warn about dizziness when standing; instruct patients to report palpitations, fainting or involuntary movements immediately.

Reinforce prescription‑only status and storage at room temperature; provide clear missed‑dose and overdose advice.

Delivery Across United Kingdom